A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT ID: NCT05238883

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-10
• Study Completion Date: 2026-12-31

Brief Summary

The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take the dose of HFB200301 as a monotherapy or in combination with tislelizumab that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

Detailed Description

This is a Phase 1a/1b, first in human, open-label, dose escalation and expansion study in adults with advanced cancers. The study will comprise of

1. A Screening Period

2. A Treatment Period during which participants will receive the study drug on the first day of each cycle

3. A Follow-up Period

Conditions

Gastric Cancer; Renal Cell Carcinoma; Melanoma; Sarcoma; Testicular Germ Cell Tumor; Cervical Cancer; Mesothelioma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Escalation - HFB200301 monotherapy

Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).

Group Type: EXPERIMENTAL

HFB200301

Intervention Type: DRUG

Participants will be administered HFB200301 as described in the experimental arm.

Dose Escalation - HFB200301 in combination with tislelizumab

Participants will be administered HFB200301 at dose levels 1-4 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Dose for Expansion (RDE).

Group Type: EXPERIMENTAL

HFB200301

Intervention Type: DRUG

Participants will be administered HFB200301 as described in the experimental arm.

Tislelizumab

Intervention Type: DRUG

Participants will be administered tislelizumab as described in the experimental arm.

Dose Expansion - HFB200301 monotherapy

Participants will be administered HFB200301 at monotherapy RDE as an intravenous infusion.

Group Type: EXPERIMENTAL

HFB200301

Intervention Type: DRUG

Participants will be administered HFB200301 as described in the experimental arm.

Dose Expansion - HFB200301 in combination with tislelizumab

Participations will be administered HFB200301 in combination with tislelizumab at combination RDE as an intravenous infusion.

Group Type: EXPERIMENTAL

HFB200301

Intervention Type: DRUG

Participants will be administered HFB200301 as described in the experimental arm.

Tislelizumab

Intervention Type: DRUG

Participants will be administered tislelizumab as described in the experimental arm.

Interventions

HFB200301

Participants will be administered HFB200301 as described in the experimental arm.

Intervention Type: DRUG

Tislelizumab

Participants will be administered tislelizumab as described in the experimental arm.

Intervention Type: DRUG

Other Intervention Names

BGB-A317

Eligibility Criteria

Inclusion Criteria

• Previously received the following lines of systemic therapy for the advanced/metastatic disease:

• Gastric cancer: at least 2 lines of therapy
• Renal cell carcinoma: at least 2 lines of therapy
• Melanoma:

• BRAF V600E mutant: must have received at least 2 lines of therapy
• BRAF V600E wild type: must have received at least 1 line of therapy
• Sarcoma: at least 1 line of therapy
• Testicular germ cell tumor: at least 2 lines of therapy
• Cervical cancer: at least 2 lines of therapy
• Mesothelioma: at least 2 lines of therapy
• Non-small cell lung cancer: at least 2 lines of therapy
• Head and neck squamous cell carcinoma: at least 2 lines of therapy
• Suitable site to biopsy at pre-treatment and on-treatment
• Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or modified RECIST (mRECIST) for mesothelioma
• Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion Criteria

• Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy
• For soft tissue sarcoma and testicular germ cell tumor patients only: prior immune therapy
• Therapeutic radiation therapy within the past 2 weeks
• Prior exposure to agents targeting the Tumor Necrosis Factor Receptor type 2 (TNFR2) receptor
• Active autoimmune disease requiring systemic treatment in the previous 2 years
• Systemic steroid therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive therapy ≤ 14 days before first dose
• Persisting toxicity of ≥Grade 2 (≥Grade 1 for diarrhea) relating to prior anti cancer therapy with the following exceptions:

• All grades of alopecia are acceptable
• Endocrine dysfunction on replacement therapy is acceptable
• Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition
• Major surgery within 4 weeks of the first dose of study drug
• History or presence of drug or non-drug induced interstitial lung disease or pneumonitis ≥Grade 2. For combination only: non-small cell lung cancer patients, mesothelioma or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening
• History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any excipient of HFB200301
• Using sensitive substrates of major cytochrome P450 (CYP450) enzymes
• Known active malignancy, with the exception of the specific cancer under investigation in this trial, that required treatment within the previous 2 years
• For combination only:

• Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out
• Hypersensitivity to tislelizumab or any of its excipients.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HiFiBiO Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Mayo Clinic

Scottsdale, Arizona, United States

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States

Mayo Clinic

Jacksonville, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University School of Medicine

St Louis, Missouri, United States

The University of Texas, MD Anderson Cancer Center

Houston, Texas, United States

NEXT Virginia Cancer Specialists

Fairfax, Virginia, United States

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Hospital Universitario 12 de Octubre

Madrid, , Spain

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Countries

United States; Spain

References

Gao Z, Zhang Q, Chen H, Chen J, Kang J, Yu H, Song Y, Zhang X. TNFR2 promotes pancreatic cancer proliferation, migration, and invasion via the NF-kappaB signaling pathway. Aging (Albany NY). 2023 Aug 16;15(16):8013-8025. doi: 10.18632/aging.204941. Epub 2023 Aug 16.

Reference Type: DERIVED

PMID: 37589506 (View on PubMed)

Other Identifiers

2021-006231-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2024-511286-11-00

Identifier Type: CTIS

Identifier Source: secondary_id

HFB-200301-01

Identifier Type: -

Identifier Source: org_study_id